Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Share-based Compensation (2016 - 2025)

Marimed (MRMD) has disclosed Share-based Compensation for 11 consecutive years, with $422000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 51.8% to $422000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, up 80.95% year-over-year, with the annual reading at $1.9 million for FY2025, 80.95% up from the prior year.
  • Share-based Compensation for Q4 2025 was $422000.0 at Marimed, up from $382000.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $5.6 million in Q3 2021, with the low at -$58000.0 in Q4 2022.
  • Average Share-based Compensation over 5 years is $950388.9, with a median of $339500.0 recorded in 2023.
  • Peak annual rise in Share-based Compensation hit 477.59% in 2023, while the deepest fall reached 91.58% in 2023.
  • Over 5 years, Share-based Compensation stood at $5.6 million in 2021, then tumbled by 101.04% to -$58000.0 in 2022, then skyrocketed by 477.59% to $219000.0 in 2023, then grew by 26.94% to $278000.0 in 2024, then surged by 51.8% to $422000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $422000.0, $382000.0, and $549000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.